Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Gains from Sales and Divestitures (2022 - 2026)

Organogenesis Holdings has reported Gains from Sales and Divestitures over the past 4 years, most recently at $1.6 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 14.32% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 14.32%, while the annual FY2025 figure was $1.6 million, 14.32% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $1.6 million at Organogenesis Holdings, up from $1.6 million in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $1.6 million in Q4 2025 and troughed at $239245.0 in Q2 2022.
  • A 4-year average of $984774.5 and a median of $1.4 million in 2024 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 230.35% in 2024 and later rose 10.67% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $249106.0 in 2022, then soared by 109.81% to $522651.0 in 2023, then soared by 174.53% to $1.4 million in 2024, then increased by 14.32% to $1.6 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ORGO at $1.6 million in Q4 2025, $1.6 million in Q3 2025, and $1.6 million in Q2 2025.